6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04332276 (ClinicalTrials.gov) | September 18, 2020 | 25/3/2020 | Dopaminergic restauratIon by intraVEntriculaire Administration | A New Concept of Continuous Dopaminergic Stimulation by Cerebroventricular Administration of A-dopamine (Dopamine Stored in Anaerobia) for Severe Motor Fluctuations in Parkinson's Disease? | Parkinson Disease | Drug: A-dopamine;Drug: optimized oral treatment | University Hospital, Lille | InBrain Pharma | Recruiting | 45 Years | 75 Years | All | 20 | Phase 1/Phase 2 | France |
| 2 | EUCTR2020-000155-12-FR (EUCTR) | 12/05/2020 | 14/01/2020 | Dopaminergic restauratIon controlled by intraventriculaire administration | A new concept of continuous dopaminergic stimulation by cerebroventricular administration of A-dopamine (dopamine stored in anaerobia) for severe motor fluctuations in Parkinson’s disease? - DIVE-I | Proof of concept study: prospective, monocentric, controlled randomized study according a cross over design with 2 groups: cerebroventricular administration of A-dopamine versus optimized oral treatment in patients with Parkinson’s disease at the stage of severe motor complications related with oral L-dopa (fluctuations and dyskinesia). ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Solution de chlorhydrate de dopamine anaérobie Product Code: A-dopamine | InBrain Pharma SAS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 1;Phase 2 | France |